<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586803</url>
  </required_header>
  <id_info>
    <org_study_id>SHR4640-Ⅰ-109</org_study_id>
    <nct_id>NCT04586803</nct_id>
  </id_info>
  <brief_title>Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers</brief_title>
  <official_title>Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers (Single Center, Randomized, Open, 3 Cycles, 6 Sequences)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the relative bioavailability of three&#xD;
      different prescription processes of SHR4640 tablets in healthy volunteers. The secondary&#xD;
      objective of the study is to observe the safety of SHR4640 tablets in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Enrollment: Number of Subjects: 24 Type: Anticipated&#xD;
&#xD;
      Allocation : Yes Intervention Model : Single center, randomized, open Intervention Model&#xD;
      Description: 3 cycles, 6 sequences Masking: No Masking&#xD;
&#xD;
      Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six&#xD;
      groups of subjects were respectively given A version or C version or D version of SHR4640&#xD;
      tablet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day1 to Day25</time_frame>
    <description>Peak plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Day1 to Day25</time_frame>
    <description>Area under the curve from the time of dosing. Dosing time to the last measurable (positive) concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf(if available)</measure>
    <time_frame>Day1 to Day25</time_frame>
    <description>Area under the curve from time 0 to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day1 to Day25</time_frame>
    <description>Time of maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Day1 to Day25</time_frame>
    <description>Half time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Day1 to Day25</time_frame>
    <description>apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Day1 to Day25</time_frame>
    <description>apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD</measure>
    <time_frame>Day1 to Day25</time_frame>
    <description>concentration of serum urine acid</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Primary Gout</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR4640</intervention_name>
    <description>Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Voluntarily sign the informed consent form before the start of the activities&#xD;
             related to this trial, and be able to understand the procedures and methods of this&#xD;
             trial, and be willing to strictly abide by the clinical trial plan to complete this&#xD;
             trial; 2) Aged between 18 and 45 years old (including both ends, whichever is the time&#xD;
             of signing the informed consent form), male; 3) Body weight ≥ 50 kg, and body mass&#xD;
             index (BMI): 19-26 kg/m2 (both ends included).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will not be allowed to enter this study if they meet any of the following&#xD;
             criteria:&#xD;
&#xD;
             1. General situation:&#xD;
&#xD;
               1. Have a fertility plan within 3 months after screening to the last medication, or&#xD;
                  refuse to use medically approved contraceptive methods;&#xD;
&#xD;
               2. Drug abusers or drug urine screening positive;&#xD;
&#xD;
               3. Smokers (average daily smoking 5 or more) or urine Nicotin positive.&#xD;
&#xD;
               4. The average daily alcohol intake during the first month was more than 25 g (for&#xD;
                  example, 750 mL beer, 250 mL wine or 50 mL low spirits);&#xD;
&#xD;
               5. Anyone who had eaten grapefruit or fruit juice products within 2 days before&#xD;
                  administration, any food or drink containing caffeine (such as coffee, tea,&#xD;
                  chocolate, cola or other caffeinated carbonated drinks, etc.) and foods or drinks&#xD;
                  rich in purine food or alcohol.&#xD;
&#xD;
               6. The researchers judged that the subjects had medical conditions that affected the&#xD;
                  absorption, distribution, metabolism and excretion of drugs or reduced&#xD;
                  compliance.&#xD;
&#xD;
             2. Laboratory tests showed the following conditions:&#xD;
&#xD;
               1. Those with sUA &gt; 420 µmol / L during the screening period, or those with a&#xD;
                  previous history of hyperuricemia and / or gout;&#xD;
&#xD;
               2. Those with estimated glomerular filtration rate (eGFR) &lt; 90 during the screening&#xD;
                  period;&#xD;
&#xD;
               3. Those with urolithiasis indicated or suspected by B ultrasound during the&#xD;
                  screening period;&#xD;
&#xD;
               4. Those who were positive for hepatitis B surface antigen (HBsAg), anti-hepatitis C&#xD;
                  virus (HCV) antibody, human immunodeficiency virus (HIV) antibody or syphilis&#xD;
                  antibody within one month or during the screening period.&#xD;
&#xD;
             3. There is any history of any of the following or concomitant diseases:&#xD;
&#xD;
               1. Any clinical history of serious illness or disease or condition that the&#xD;
                  researchers believe may affect the results of the trial, including, but not&#xD;
                  limited to, a history of circulatory, endocrine, nervous, digestive, urinary or&#xD;
                  hematological, immune, mental and metabolic diseases.&#xD;
&#xD;
               2. People with allergies, including those who are explicitly allergic to research&#xD;
                  drugs or any ingredient in research drugs, are allergic to any food ingredient or&#xD;
                  have special requirements for diet, and are unable to follow a uniform diet;&#xD;
&#xD;
               3. Screening those who have undergone any operation within the first 3 months, or&#xD;
                  who have not recovered after the operation, or who may have a plan for operation&#xD;
                  or hospitalization during the trial;&#xD;
&#xD;
               4. Those who donated blood (or lost blood) within the first 3 months and donated&#xD;
                  blood (or lost blood) more than 400 mL, or received blood transfusion.&#xD;
&#xD;
             4. Use any of the following drugs or participate in clinical trials:&#xD;
&#xD;
               1. Screen people who have participated in clinical trials of any drug or medical&#xD;
                  device within the previous 3 months;&#xD;
&#xD;
               2. Take any prescription drug, over-the-counter medicine, Chinese herbal medicine or&#xD;
                  dietary supplement within 2 weeks before the screening period.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zourong Ruan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The second affiliated Hospital of Medical College of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheng Zhong, Master</last_name>
    <phone>13564101315</phone>
    <phone_ext>+86</phone_ext>
    <email>zhongsheng@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuxiong Gao, PhD</last_name>
    <phone>19821262236</phone>
    <phone_ext>+86</phone_ext>
    <email>gaoyuxiong@hrglobe.cn</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

